File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intimate partner violence during pregnancy: To screen or not to screen?

TitleIntimate partner violence during pregnancy: To screen or not to screen?
Authors
KeywordsAcademia-community-industrial partnerships
Intimate partner violence
Maternal outcomes
Postnatal depression
Universal screening
Issue Date1-Dec-2024
PublisherElsevier
Citation
Best Practice and Research: Clinical Obstetrics and Gynaecology, 2024, v. 97 How to Cite?
Abstract

Intimate partner violence (IPV) during pregnancy emerges as a compelling and urgent concern within the domain of public health, casting a long shadow over a substantial cohort of women. Its pernicious consequences extend beyond the individual, enveloping the well-being of both the mother and the fetus, giving rise to an elevated risk of preterm birth, low birth weight, fetal harm, and maternal psychological distress, including depression, anxiety, post-traumatic stress disorder, and, tragically, maternal mortality. Despite the prevalence of IPV being comparable to other conditions like gestational diabetes and preeclampsia, a universal screening protocol for IPV remains absent globally. We reviewed the clinical guidelines and practices concerning IPV screening, painstakingly scrutinizing their contextual nuances across diverse nations. Our study unveils multifaceted challenges of implementing universal screening. These hurdles encompass impediments to victim awareness and disclosure, limitations in healthcare providers' knowledge and training, and the formidable structural barriers entrenched within healthcare systems. Concurrently, we delve into the potential biomarkers intricately entwined with IPV. These promising markers encompass inflammatory indicators, epigenetic and genetic influences, and a diverse array of chemical compounds and proteins. Lastly, we discussed various criteria for universal screening including (1) valid and reliable screening tool; (2) target population as pregnant women; (3) scientific evidence of screening programme; and (4) integration of education, testing, clinical services, and programme management to minimise the challenges, which are paramount. With the advancement of digital technology and various biomarkers identification, screening and detecting IPV in clinical settings can be conducted systemically. A systems-level interventions with academia-community-indutrial partnerships can help connect pregnant women to desire support services to avoid adverse maternal and child health outcomes.


Persistent Identifierhttp://hdl.handle.net/10722/350206
ISSN
2023 Impact Factor: 3.9
2023 SCImago Journal Rankings: 1.532

 

DC FieldValueLanguage
dc.contributor.authorWong Janet Yuen-Ha-
dc.contributor.authorZhu, Shiben-
dc.contributor.authorMa, Haixia-
dc.contributor.authorIp Patrick-
dc.contributor.authorChan, Ko Ling-
dc.contributor.authorLeung Wing Cheong-
dc.date.accessioned2024-10-21T03:56:51Z-
dc.date.available2024-10-21T03:56:51Z-
dc.date.issued2024-12-01-
dc.identifier.citationBest Practice and Research: Clinical Obstetrics and Gynaecology, 2024, v. 97-
dc.identifier.issn1521-6934-
dc.identifier.urihttp://hdl.handle.net/10722/350206-
dc.description.abstract<p>Intimate partner violence (IPV) during pregnancy emerges as a compelling and urgent concern within the domain of public health, casting a long shadow over a substantial cohort of women. Its pernicious consequences extend beyond the individual, enveloping the well-being of both the mother and the fetus, giving rise to an elevated risk of preterm birth, low birth weight, fetal harm, and maternal psychological distress, including depression, anxiety, post-traumatic stress disorder, and, tragically, maternal mortality. Despite the prevalence of IPV being comparable to other conditions like gestational diabetes and preeclampsia, a universal screening protocol for IPV remains absent globally. We reviewed the clinical guidelines and practices concerning IPV screening, painstakingly scrutinizing their contextual nuances across diverse nations. Our study unveils multifaceted challenges of implementing universal screening. These hurdles encompass impediments to victim awareness and disclosure, limitations in healthcare providers' knowledge and training, and the formidable structural barriers entrenched within healthcare systems. Concurrently, we delve into the potential biomarkers intricately entwined with IPV. These promising markers encompass inflammatory indicators, epigenetic and genetic influences, and a diverse array of chemical compounds and proteins. Lastly, we discussed various criteria for universal screening including (1) valid and reliable screening tool; (2) target population as pregnant women; (3) scientific evidence of screening programme; and (4) integration of education, testing, clinical services, and programme management to minimise the challenges, which are paramount. With the advancement of digital technology and various biomarkers identification, screening and detecting IPV in clinical settings can be conducted systemically. A systems-level interventions with academia-community-indutrial partnerships can help connect pregnant women to desire support services to avoid adverse maternal and child health outcomes.</p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofBest Practice and Research: Clinical Obstetrics and Gynaecology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAcademia-community-industrial partnerships-
dc.subjectIntimate partner violence-
dc.subjectMaternal outcomes-
dc.subjectPostnatal depression-
dc.subjectUniversal screening-
dc.titleIntimate partner violence during pregnancy: To screen or not to screen? -
dc.typeArticle-
dc.identifier.doi10.1016/j.bpobgyn.2024.102541-
dc.identifier.scopuseid_2-s2.0-85203531222-
dc.identifier.volume97-
dc.identifier.issnl1521-6934-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats